Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fentanyl hydrochloride
Drug ID BADD_D00881
Description Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.[A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.[A179542] In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths).[L6748] Opioid overdoses kill an average of 11 Canadians daily.[L6751] Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]
Indications and Usage For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
Marketing Status Prescription; Discontinued
ATC Code N01AH01; N02AB03
DrugBank ID DB00813
KEGG ID D10811
MeSH ID D005283
PubChem ID 83932
TTD Drug ID D0E1WI
NDC Product Code 0406-1165
Synonyms Fentanyl | Phentanyl | Fentanest | Fentanyl Citrate | R-4263 | R 4263 | R4263 | Sublimaze | Transmucosal Oral Fentanyl Citrate | Duragesic | Durogesic | Fentora
Chemical Information
Molecular Formula C22H29ClN2O
CAS Registry Number 1443-54-5
SMILES CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Drug tolerance increasedMu-type opioid receptorP35372T47768Not Available
Drug tolerance increasedAdenylate cyclase type 1Q08828T63609Not Available
PainAbscisic acid-inducible protein kinaseQ02066Not AvailableNot Available
PainOpioid growth factor receptorQ9NZT2T13741Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary retention20.02.02.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urogenital disorder21.10.05.010; 20.08.01.002--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Wound secretion12.01.08.007; 08.01.03.035--Not Available
Application site vesicles08.02.01.009; 23.03.01.009; 12.07.01.009--Not Available
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.011--Not Available
Application site papules23.03.03.022; 12.07.01.025; 08.02.01.025--Not Available
Application site pustules23.03.10.004; 12.07.01.041; 11.01.12.014; 08.02.01.041--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Wound haemorrhage12.01.08.017; 24.07.01.029--Not Available
Wound complication12.01.08.010--
Inflammation of wound12.01.08.034; 08.01.05.012--Not Available
Haemorrhage24.07.01.002--Not Available
Vasodilation procedure25.03.01.001--Not Available
Application site discolouration12.07.01.030; 08.02.01.030; 23.03.03.023--Not Available
The 4th Page    First    Pre   4    Total 4 Pages